Obinutuzumab for refractory minimal change disease in obese patients: a case series - Quiz - MDSpire

Obinutuzumab for refractory minimal change disease in obese patients: a case series

  • By

  • Dandan Xue

  • Xiaofen Ma

  • Xiang Li

  • Yiming Zhang

  • Bing Xue

  • May 14, 2026

  • 0 min

Share

Original Source(s)

Obinutuzumab for refractory minimal change disease in obese patients: a case series

  • by Dandan Xue, Xiaofen Ma, Xiang Li, Yiming Zhang, Bing Xue

  • May 14, 2026

Related Content

Investigating Metabolic and Inflammatory Patterns in Staging Cardiovascular-Kidney-Metabolic Syndrome: A Comparative Cross-Sectional Analysis

Examining the Link Between a Modified Cardiometabolic Index and Cardiovascular Disease Risk in Adults with Early Cardiovascular-Kidney-Metabolic Syndrome: Findings from a Prospective Cohort Study

Pregestational Cardiometabolic Biomarkers and Future Hypertensive Disorders of Pregnancy